Brief exposure to hyperglycemia activates dendritic cells in vitro and in vivo. Issue 6 (1st November 2019)

• Record Type: Journal Article
• Authors: Thomas, Aline M.; Dong, Ying; Beskid, Nicholas M.; García, Andrés J.; Adams, Andrew B.; Babensee, Julia E.
• Is Part Of: Journal of cellular physiology. Volume 235:Issue 6(2020:Jun.)
• Page Start: 5120
• Page End: 5129
• Publication Date: 2019-11-01
• Subjects: dendritic cells -- diabetes -- hydrogel -- hyperglycemia -- immunity -- interleukin‐10; Physiology -- Periodicals; Cell physiology -- Periodicals; 571.6
• DOI: 10.1002/jcp.29380
• Languages: English
• ISSNs: 0021-9541

Abstract

Abstract: Dendritic cells are key players in regulating immunity. These cells both activate and inhibit the immune response depending on their cellular environment. Their response to hyperglycemia, a condition common amongst diabetics wherein glucose is abnormally elevated, remains to be elucidated. In this study, the phenotype and immune response of dendritic cells exposed to hyperglycemia were characterized in vitro and in vivo using the streptozotocin‐induced diabetes model. Dendritic cells were shown to be sensitive to hyperglycemia both during and after differentiation from bone marrow precursor cells. Dendritic cell behavior under hyperglycemic conditions was found to vary by phenotype, among which, tolerogenic dendritic cells were particularly sensitive. Expression of the costimulatory molecule CD86 was found to reliably increase when dendritic cells were exposed to hyperglycemia. Additionally, hydrogel‐based delivery of the anti‐inflammatory molecule interleukin‐10 was shown to partially inhibit these effects in vivo. Abstract : In this study, the phenotype and immune response of dendritic cells exposed to hyperglycemia were characterized in vitro and in vivo using the streptozotocin (STZ)‐induced diabetes model. Expression of the costimulatory molecule CD86 was found to reliably increase when dendritic cells were exposed to hyperglycemia. Additionally, hydrogel‐based delivery of the anti‐inflammatory molecule interleukin‐10 (IL‐10) was shown to partially inhibit these effects in vivo.